Abstract 58P
Background
Medulloblastomas are a rare disease in adult population. Currently the main treatment consists in surgical resection. There is a lack of prospective evidence and the adequate regimen of chemotherapy and radiotherapy is yet to be defined.
Methods
We conducted a retrospective study including adult patients with medulloblastoma treated at a tertiary referral center. The aim of this study was to estimate Overall survival (OS) and disease-free survival (DFS).
Results
We identified a total of 58 patients. Median age was 28 years (range 16 – 62). A total of 26 patients, (44%) received at least one chemotherapy regimen. The most frequent combination was Vincristine/Cisplatin/Cyclophosphamide (VPC) (29%). 43% were treated with a concomitant chemoradiotherapy. DFS was 35.5 months, (range 4-100 months). Patients who underwent partial tumor removal presented 62-month OS. Patients with total resection surgery did not reach median OS (HR 1.98, CI 0.67 – 5.8). Those treated with chemotherapy did not reach OS. Patients without chemotherapy regimen have 62-month OS (HR 0.6 CI 0.19 – 1.8) Patients treated with VPC did not meet median overall survival, meanwhile other regimen implementations demonstrated 43-month OS (HR 2.00 CI 0.71 – 5.62) (p = 0.18). Patients who wereńt treated with chemoradiotherapy did not reach OS vs patients treated with sequential radiotherapy and chemotherapy (HR 0.65, CI 0.21 – 1.99) (P 0.45). Performance status was an important predictor of OS, patients with ECOG 3 demonstrated 12 months of OS meanwhile patients with ECOG 0 – 2 did not reach a median OS (HR 2.7, CI 1.63 – 4.55). Related to adverse events, 16% of patients treated with chemotherapy presented grade 3 and 4 toxicity. 10% of these patients manifested grade 3 or 4 neutropenia. A total of 51 pts (88%) received radiotherapy. 22 patients developed radioepithelitis (38%) and 13 pts developed radiotherapy-associated CNS toxicity.
Conclusions
In this study of 58 adult patients diagnosed with Medulloblastoma the results showed a performance status as an important OS prognostic factor. Sequential chemotherapy or concomitant therapy did not show an OS significance probably related to the size of our population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract